Trial Profile
A Phase 3, Single-Blind Study to Evaluate the Effect of Eleclazine (GS-6615) on Shortening of the QT Interval, Safety, and Tolerability in Subjects With Long QT Syndrome Type 3
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Eleclazine (Primary)
- Indications Long QT syndrome
- Focus Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 15 Nov 2017 Primary endpoint (Difference between mean daytime QT interval corrected for heart rate (QTc) at baseline and at Week 24 (based on standard 12-lead ECG data)) has been met as per the results presented at the 90th Annual Scientific Sessions of the American Heart Association
- 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association
- 24 Feb 2017 Status changed from active, no longer recruiting to discontinued.